https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/ALGN/align-technology-patent-infringement-case-angelalign BiopharmaWatch en 2026-10-17T01:11:00.000Z Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent Court https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-new-employees-nasdaq-listing-rule-5635-20261016 BiopharmaWatch en 2026-10-16T21:34:00.000Z Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261016 BiopharmaWatch en 2026-10-16T21:15:00.000Z Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inducement-grants-new-employees BiopharmaWatch en 2026-10-16T21:00:00.000Z Actinium Pharmaceuticals Announces Inducement Grants to New Employees https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261016 BiopharmaWatch en 2026-10-16T20:20:00.000Z Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-nasdaq-listing-rule-20261016 BiopharmaWatch en 2026-10-16T20:15:00.000Z Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261016 BiopharmaWatch en 2026-10-16T20:15:00.000Z Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-20261016 BiopharmaWatch en 2026-10-16T20:05:00.000Z 4DMT Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/KRRO/korro-bio-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-16T20:05:00.000Z Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VTRS/viatris-fda-approval-ryzumvi-presbyopia BiopharmaWatch en 2026-10-16T20:05:00.000Z Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-chardan-healthcare-conference-2026 BiopharmaWatch en 2026-10-16T20:01:00.000Z Prelude Therapeutics to Participate in the Chardan Healthcare Conference https://www.biopharmawatch.com/news/ALC/fda-approves-alcon-brytly-eye-drops BiopharmaWatch en 2026-10-16T19:57:00.000Z FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes https://www.biopharmawatch.com/news/IRD/opus-genetics-fda-approval-phentolamine-presbyopia BiopharmaWatch en 2026-10-16T16:00:00.000Z Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia https://www.biopharmawatch.com/news/IBRX/immunitybio-phase-3-data-cystectomy-avoidance BiopharmaWatch en 2026-10-16T15:49:00.000Z ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors